AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics
October 19-23, 2013
Hynes Convention Center
Boston, MA, USA
Abstract submission deadline: Monday, August 12
Early registration deadline: Friday, August 9
Housing, registration, and abstract submission will open in mid-June.
SCIENTIFIC COMMITTEE CO-CHAIRPERSONS:
Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA (AACR)
Lee J. Helman, National Cancer Institute, Bethesda, MD, USA (NCI)
Sabine Tejpar, Catholic University of Leuven, Leuven, Belgium (EORTC)
ORGANIZING COMMITTEE CO-CHAIRPERSONS:
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA (AACR)
James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Roger Stupp, University Hospital (CHUV), Lausanne, Switzerland (EORTC)
Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2013 Molecular Targets and Cancer Therapeutics conference will bring together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomized, multicentre cancer clinical trials. This requires a joint and global approach, and early and optimal exchange of information.
SCIENTIFIC COMMITTEE:
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA (AACR)
Ahmad H. Awada, Institut Jules Bordet, Brussels, Bruxelles, Belgium (EORTC)
Jan Bogaerts, EORTC, Brussels, Belgium (EORTC)
Fatima Cardoso, Champalimaud Cancer Center, Lisbon, Portugal (EORTC)
Phillippe Cassier, Centre Léon Bérard, Lyon, France (EORTC)
David D. Chang, Amgen, Inc., Thousand Oaks, CA, USA (AACR)
Helen X. Chen, National Cancer Institute-CTEP, Rockville, MD, USA (NCI)
Elizabeth Cohen-Jonathan, Institut Claudius Regaud, Toulouse, France (EORTC)
Jerry M. Collins, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Barbara A. Conley, National Cancer Institute, DCTD, Rockville, MD, USA (NCI)
Sara A. Courtneidge, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA (AACR)
Christian Dittrich, Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria (EORTC)
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
Dean Fennell, Leicester Royal Infirmary, Leicester, United Kingdom (EORTC)
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
Toby Tucker Hecht, National Cancer Institute, Rockville, MD, USA (NCI)
Lee J. Helman, National Cancer Institute, Bethesda, MD, USA (NCI)
S. Percy Ivy, National Cancer Institute-DCTD, Rockville, MD, USA (NCI)
Paula M. Jacobs, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Bernd Kasper, University of Heidelberg, Heidelberg, Germany (EORTC)
Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Denis A. Lacombe, EORTC, Brussels, Belgium (EORTC)
Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA, USA (AACR)
Lisa Licitra, Istituto Nazionale dei Tumori, Milan, Italy (EORTC)
W. Marston Linehan, National Cancer Institute, Bethesda, MD (NCI)
Iwona Lugowska, Maria Sklodowkiej-Curie Memorial Cancer Center, Warsaw, Poland (EORTC)
Philippe Maingon, Centre Georges-François Leclerc, Dijon, France (EORTC)
Elaine Mardis, Washington University School of Medicine, Saint Louis, MO, USA (AACR)
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Kenneth P. Olive, Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA (AACR)
Ralph E. Parchment, SAIC-Frederick, Inc., Frederick, MD, USA (NCI)
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA (NCI)
Victoria M. Richon, Sanofi Oncology, Wellesley Hills, MA, USA (AACR)
Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA (AACR)
Emad Shash, EORTC, Brussels, Belgium (EORTC)
Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA, USA (AACR)
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA (AACR)
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (EORTC)
Patricia S. Steeg, National Cancer Institute, Bethesda, MD, USA (NCI)
Louis M. Staudt, National Cancer Institute, Bethesda, MD (NCI)
Charles Swanton, Cancer Research UK, London, United Kingdom (EORTC)
Beverly A. Teicher, National Cancer Institute, Rockville, MD, USA (NCI)
Joseph E. Tomaszewski, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA (AACR)
Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA, USA (AACR)
Barbara L. Weber, Novartis Institutes for BioMedical Research, Cambridge, MA, USA (AACR)
Mickey Williams, National Cancer Institute-DCTD, Frederick, MD, USA (NCI)
John J. Wright, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
Michael B. Yaffe, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA, USA (AACR)
James A. Zwiebel, National Cancer Institute-DCTD, Bethesda, MD, USA (NCI)
The American Association for Cancer Research (AACR) is a nonprofit scientific society that includes 33,000 laboratory, translational and clinical cancer researchers whose mission is to prevent and cure cancer through research, education, communication and collaboration.
The National Cancer Institute (NCI), founded in 1937, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.
The European Organization for Research and Treatment of Cancer (EORTC), founded in 1962, conducts, develops, coordinates and stimulates clinical and translational research in Europe to improve the management of cancer and related problems by increasing survival and quality of life for patients with cancer.